Invest
27 Years
4.4 Star
1 Crore +
Pharmaceuticals company Strides Pharma Science announced Q4FY24 & FY24 results:
Q4FY24 Financial Highlights:
- Highest ever quarterly Revenue of Rs 10,583 million
- Gross Margin returned to a historic high of 60.7% in Q4FY24
- Highest ever quarterly EBITDA of Rs 2,040 million
FY24 Financial Highlights:
- Highest ever full-year Revenue of Rs 40,555 million in FY24, up 14.4% YoY
- Highest ever full-year EBITDA of Rs 7,477 million in FY24, up 77.6% YoY
- US business achieved top end of USD 250 million revenue outlook for FY24, grew by 11.8% YoY
- Net Debt reduced by Rs 3,131 million in FY24
- Net Debt to EBITDA improved to 2.72x in FY24
Arun Kumar, Founder, Executive Chairperson & Managing Director, commented on the performance and said, “FY24 was an exceptional year for Strides, marked by the successful completion of our Reset strategy initiated in FY22. The company achieved all its key objectives laid down in our Reset strategy and has bounced back to become a strong and resilient company.
As a result of our focus on consistent growth and cost containment, FY24 concluded as the best year in the Company’s history in terms of both Revenue and absolute EBITDA.
With today’s leadership announcement, we have introduced a well-structured succession and leadership development program, guided by the Board. I am confident that the strong internal talent we have developed over the years will ensure the company's continued long-term growth. In the near term, we will continue to focus on operating cash flows while investing in growth to ensure that the efforts of our Reset are balanced by an improved revenue CAGR, in the coming years. Our ESG efforts have started to yield results, with our EcoVadis rating improving from 30 to 44 during the first year of review. We will continue to intensify our efforts to become a more sustainable and responsible company”.
FAQ’s on Strides Pharma Science Ltd Shares
